Fuzhou Tuoxin Tiancheng Biotechnology

Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. (Tcelltech) is a clinical-stage biopharmaceutical company established in 2017, focusing on the development of innovative immunotherapies for solid tumors. The company was co-founded by Dr. Lieping Chen, a world-renowned tumor immunologist, and Dr. Gangxiong Huang, an expert in cell therapy. Tcelltech aims to overcome the challenges of treating solid tumors, such as high heterogeneity and immunosuppression, by developing a new generation of T-cell immunotherapy drugs.

Tcelltech’s core business revolves around the research, development, and production of cell-based therapeutic technologies. The company's main product, TX-103, is an autologous CAR-T cell therapy that targets B7-H3, a protein found on various solid tumors. TX-103 has shown promising results in treating recurrent glioblastoma (rGBM), one of the most aggressive types of brain cancer. Clinical trials have indicated that TX-103 can significantly extend the survival of rGBM patients, who otherwise have a very poor prognosis. The therapy has received clinical trial approvals in both China and the United States and is currently undergoing multi-center international trials.

The company's business model is centered on the entire drug development process, from initial research and development to clinical-grade production, quality management, and clinical studies. Tcelltech serves biomedical research institutions and healthcare providers. The company has successfully raised significant capital to advance its clinical programs, including a Series B financing round of nearly $40 million in July 2025. This funding is being used to advance the clinical development of TX-103, support the research of other pipeline products, and expand the company's team and international presence.

Keywords: CAR-T cell therapy, solid tumors, immunotherapy, biopharmaceutical, oncology, glioblastoma, B7-H3, clinical trials, T-cell therapy, cancer treatment, cell-based therapeutics, drug development, recurrent brain cancer, neuro-oncology, gene therapy, biomedical research, life sciences, therapeutic devices, clinical-stage, venture capital-backed